Clinical symptoms:
Increased LDL cholesterol and lipoprotein(a) are amongst the most important risk factors in the development of atherosclerosis and therefore of coronary heart disease (CHD). Cardiovascular diseases are the leading cause of death, with coronary heart disease (CHD) predominating. (Source: Fresenius brochure “DALI – Direct Adsorption of Lipoproteins”)
It has been shown that reducing atherogenic LDL cholesterol or Lp(a) prevents the progression of atherosclerotic changes and can even bring about a regression in the pathological processes.
